These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36585757)

  • 21. Generalized pustular psoriasis occurred immediately after the withdrawal of upadacitinib in a patient with plaque psoriasis with inflammatory arthritis.
    Ikumi N; Fujita H; Wada TT
    J Dermatol; 2023 Dec; 50(12):e398-e399. PubMed ID: 37452475
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 23. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
    Vender RB; Lynde CW
    J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
    Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recalcitrant psoriatic uveitis and anti-tumor necrosis factor-α monoclonal antibodies: experience from a psoriasis referral center.
    Fotiadou C; Lazaridou E; Kemanetzi C; Kyrmanidou E; Ioannides D
    Int J Dermatol; 2015 Sep; 54(9):1105-8. PubMed ID: 25557117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
    Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.
    Llorenç V; Mesquida M; Sainz de la Maza M; Blanco R; Calvo V; Maíz O; Blanco A; de Dios-Jiménez de Aberásturi JR; Adán A
    Ocul Immunol Inflamm; 2016; 24(2):167-72. PubMed ID: 25325834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
    Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
    Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
    J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
    Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
    J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database.
    Oelke KR; Chambenoit O; Majjhoo AQ; Gray S; Higgins K; Hur P
    J Comp Eff Res; 2019 Jun; 8(8):607-621. PubMed ID: 30912454
    [No Abstract]   [Full Text] [Related]  

  • 32. Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis.
    Koizumi H; Tokuriki A; Oyama N; Ido H; Sugiura K; Akiyama M; Hasegawa M
    J Dermatol; 2017 Jun; 44(6):723-724. PubMed ID: 27599405
    [No Abstract]   [Full Text] [Related]  

  • 33. TNF inhibitors for psoriasis.
    Chima M; Lebwohl M
    Semin Cutan Med Surg; 2018 Sep; 37(3):134-142. PubMed ID: 30215629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature.
    Babuna Kobaner G; Polat Ekinci A; Yilmaz Z; Copur S
    Dermatol Ther; 2018 Sep; 31(5):e12693. PubMed ID: 30225952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis.
    Dattola A; Vollono L; Cannizzaro MV; Caposiena Caro RD; Mazzilli S; Melino G; Candi E; Campione E; Bianchi L
    Ital J Dermatol Venerol; 2021 Aug; 156(4):434-439. PubMed ID: 33034437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.
    Strain J; Leis M; Lee KO; Fleming P
    Skin Therapy Lett; 2021 Mar; 26(2):1-5. PubMed ID: 33769772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A patient with psoriatic arthritis due to generalized pustular psoriasis (von Zumbusch type)].
    Seki K; Amano T; Nakayama Y
    Ryumachi; 1997 Aug; 37(4):568-73. PubMed ID: 9311283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Certolizumab pegol in the treatment of psoriasis: Real-life data.
    Turkmen M; Dogan S
    Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study.
    Chatzimichail G; Günther J; Ständer S; Thaçi D
    J Dermatolog Treat; 2022 May; 33(3):1749-1753. PubMed ID: 33430676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.